Navigation Links
Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities
Date:2/1/2010

BANGALORE, India, February 1 /PRNewswire/ -- Infinitus Clinical Research is continuing to pioneer its unique strategy. This is based on the following elements:

    - Physician leadership
    - Employee ownership
    - Sino-Indian focus
    - Flexible co-development model availability
    - Experience of big Pharma drug development programme planning
    - Experience of early stage life science company product development
    - Phase I, II and III capability within Asia for clinical evaluation of
      drugs
    - Clinical evaluation of medical devices
    - Clinically focused bioinformatics capability
    - Unique academic links and collaborations

"As former Vice-President for clinical drug development with a major US Pharma company" said CEO, Roy Drucker, "I was frustrated by the unexploited potential of India and China. Large Western CROs were inevitably forced to give up part of the cost advantage of those countries because of operating expense back at base camp. The best local players scored better on price and satisfied study deadline requirements but were incapable of assuming a product development partnership role. We strive to deliver the best of both worlds at Infinitus. "

"Our conviction that excellent medical science underpins excellent clinical research is reflected in our European headquarters location in the Department of Pharmacology at Oxford University. We recognize that a significant part of our client base is in the USA and our North American office will open shortly. We are also progressing a major oncology initiative which will enable Infinitus to deliver unparalleled speed, quality and prices for studies in all phases."

"Infinitus has also recognized the opacity of India and China to smaller western companies wishing to conduct product or corporate transactions in these countries. With established strategic partners in both locations we are currently working with clients who have products for which they are seeking to achieve marketing presence in India and China, as well as executing M&A mandates on behalf of Western clients. More recently, we have begun to serve the needs of Chinese clients wishing to bring their products to the West."

Roy Drucker: "The world of clinical product development is changing very rapidly and there are huge advantages available to those who are prepared to explore unfamiliar territory. Infinitus can make that exploration a positive experience."

About Infinitus:

Infinitus executes its clinical research activities exclusively in Asia.

Benefitting from not having to bear the overheads of a large western infrastructure, the orientation is very much towards serving the needs of an international clientele which includes early stage life science companies researching pharmaceutical and biotechnology products as well as medical devices.

Operating out of Bangalore in India and Nanjing in China, it is led by a management team with extensive experience of conceiving and executing entire clinical product development programmes for global registration purposes, as well as substantial hands-on operational experience in the relevant territory.

Its objective is to assist in curtailing the cost of product development in its clinical stages while at the same time expediting execution and adding value in every way possible.

Infinitus' product candidate and program evaluation services are used as decision support tools by investors prior to investment or to guide investment decisions, and by pharmaceutical companies prior to committing their resources to clinical programs for candidates developed in-house or before in-licensing candidates. It is supported by Scientific Advisory Board members based in Oxford University.

    http://www.infinitusglobal.com

    Media Contact:
    Dr Shailendra
    Tel: +91-80-40051521
    E-mail: bd@infinitusglobal.com/ shailendra@infinitusglobal.com/
    varada@infinitusglobal.com

SOURCE Infinitus Clinical Research Pvt. Ltd.


'/>"/>
SOURCE Infinitus Clinical Research Pvt. Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequenom Announces Addition to Clinical Advisory Board
2. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
3. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
4. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
5. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
6. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
7. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
8. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
9. Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams Pre-Clinical Development of Neuroprotective Parkinsons Therapies
10. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
11. ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):